Target species
Pigs
Indications for use
For the active immunisation of female pigs for the protection of progeny against transplacental infection caused by porcine parvovirus.
For the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by Erysipelothrix rhusiopathiae, serotype 1 and serotype 2.
Onset of immunity:
Porcine parvovirus: from the beginning of the gestation period.
E. rhusiopathiae: three weeks after completion of the basic vaccination scheme.
Duration of immunity:
Porcine parvovirus: vaccination provides foetal protection for the duration of gestation. Revaccination should be performed prior to each gestation, refer to “Dosage”
E. rhusiopathiae: vaccination protects against swine erysipelas until the time of the recommended revaccination (approximately six months after the basic vaccination scheme), refer to “Dosage”.
Contra-indications
Do not use in case of hypersensitivity to the active substances, to the adjuvants or to any of the excipients.
Special warnings for each target species
Vaccinate healthy pigs only.
Special precuations for use
Special precautions for use in animals
None.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of adverse reactions following accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Special precautions fo the protection of the environment.
Not applicable.
Adverse reactions (frequency and seriousness)
Pig:
Very common (> 1 animal / 10 animals treated) | Injection site inflammation1 |
Common (1 to 10 animals / 100 animals treated) | Elevated temperature2 |
Very rare (< 1 animal / 10 000 animals treated, including isolated reports) | Anaphylactic-type reaction3 |
1 Mild to moderate inflammation at the injection site that typically resolves within 4 days but in some cases may persist for up to 12 days post-vaccination.
2 A transient increase in body temperature within the first 6 hours after vaccination, which spontaneously resolves within 24 hours.
3 An appropriate symptomatic treatment is recommended.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary
medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing
authorisation holder or its local representative or the national competent authority via the national
reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Pregnancy and lactation:
Can be used during pregnancy and lactation.
Interaction with other medicinal products
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with UNISTRAIN PRRS (where this vaccine is authorised) and administered at one injection site. The product information of UNISTRAIN PRRS should be consulted before administration of the mixed products.
The mixed administration of UNISTRAIN PRRS and ERYSENG PARVO should only be used when vaccinating animals prior to mating.
For mixed use, the onset and duration of immunity of the parvovirus component and the onset of immunity of the Erysipelas component have been demonstrated to be equivalent to those determined for ERYSENG PARVO when used alone. However, the duration of immunity of the Erysipelas component following mixed use has not been investigated.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Administration route and dosage
Allow the vaccine to reach room temperature (15 ºC – 25 ºC) before administration.
Shake well before use.
Administer one dose of 2 ml by intramuscular injection in the neck muscles according to the following schedule:
Basic vaccination:
Pigs from 6 months of age which have not been previously vaccinated with the product should be given two injections with an interval of 3–4 weeks. The second injection should be administered 3 – 4 weeks before mating.
Revaccination:
A single injection should be given 2–3 weeks prior to each subsequent mating (approximately every 6 months).
For simultaneous use with UNISTRAIN®PRRS in sows for reproduction from 6 months of age, the mixed administration of ERYSENG®PARVO and UNISTRAIN®PRRS should only be used when vaccinating animals prior to mating.
The following instructions should be used: the contents of a single vial of UNISTRAIN PRRS should be reconstituted with the contents of a single vial of ERYSENG PARVO. A single dose (2 ml) of the mixed vaccines should be injected within a period of 2 hours via intramuscular use.
UNISTRAIN PRRS ERYSENG PARVO
10 doses + 10 doses (20 ml)
25 doses + 25 doses (50 ml)
50 doses + 50 doses (100 ml)
Symptoms of overdose (and where applicable, emergency procedures and antidotes).
No adverse reactions other than those mentioned in “Adverse reactions” were observed after the administration of a 2 -fold vaccine dose.
Special precautions for use and special conditions for use, including restrictions on teh use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable
Withdrawal periods
Zero days.